Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Joshua Thurman to Complement Inactivating Agents

This is a "connection" page, showing publications Joshua Thurman has written about Complement Inactivating Agents.

 
Connection Strength
 
 
 
4.909
 
  1. Thurman JM. Complement and the Kidney: An Overview. Adv Chronic Kidney Dis. 2020 03; 27(2):86-94.
    View in: PubMed
    Score: 0.664
  2. Thurman JM, Yapa R. Complement Therapeutics in Autoimmune Disease. Front Immunol. 2019; 10:672.
    View in: PubMed
    Score: 0.623
  3. Tomlinson S, Thurman JM. Tissue-targeted complement therapeutics. Mol Immunol. 2018 10; 102:120-128.
    View in: PubMed
    Score: 0.592
  4. Thurman JM, Frazer-Abel A, Holers VM. The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases. Arthritis Rheumatol. 2017 11; 69(11):2102-2113.
    View in: PubMed
    Score: 0.563
  5. Thurman JM, Le Quintrec M. Targeting the complement cascade: novel treatments coming down the pike. Kidney Int. 2016 10; 90(4):746-52.
    View in: PubMed
    Score: 0.514
  6. Holers VM, Tomlinson S, Kulik L, Atkinson C, Rohrer B, Banda N, Thurman JM. New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin Immunol. 2016 06; 28(3):260-7.
    View in: PubMed
    Score: 0.512
  7. Thurman JM. Complement in kidney disease: core curriculum 2015. Am J Kidney Dis. 2015 Jan; 65(1):156-68.
    View in: PubMed
    Score: 0.457
  8. McCullough JW, Renner B, Thurman JM. The role of the complement system in acute kidney injury. Semin Nephrol. 2013 Nov; 33(6):543-56.
    View in: PubMed
    Score: 0.428
  9. Vivarelli M, van de Kar N, Labbadia R, Diomedi-Camassei F, Thurman JM. A clinical approach to children with C3 glomerulopathy. Pediatr Nephrol. 2022 03; 37(3):521-535.
    View in: PubMed
    Score: 0.180
  10. Poppelaars F, Thurman JM. Complement-mediated kidney diseases. Mol Immunol. 2020 12; 128:175-187.
    View in: PubMed
    Score: 0.174
  11. Rohrer B, Long Q, Coughlin B, Renner B, Huang Y, Kunchithapautham K, Ferreira VP, Pangburn MK, Gilkeson GS, Thurman JM, Tomlinson S, Holers VM. A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration. Adv Exp Med Biol. 2010; 703:137-49.
    View in: PubMed
    Score: 0.082
  12. Thorgersen EB, Ghebremariam YT, Thurman JM, Fung M, Nielsen EW, Holers VM, Kotwal GJ, Mollnes TE. Candidate inhibitors of porcine complement. Mol Immunol. 2007 Mar; 44(8):1827-34.
    View in: PubMed
    Score: 0.066
  13. Antonucci L, Thurman JM, Vivarelli M. Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities. Pediatr Nephrol. 2024 May; 39(5):1387-1404.
    View in: PubMed
    Score: 0.053
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)